Paliperidone Palmitate Efficacy and Safety in Bipolar Disorder Complicated by Alcoholism
Status:
Withdrawn
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The primary specific aim is to examine the efficacy of Paliperidone extended release
Paliperidone Palmitate Injection (INVEGA® SUSTENNA™) compared to placebo in decreasing manic
symptoms in patients with comorbid DSM-IV bipolar disorder and alcohol dependence. The
investigators hypothesize that the Paliperidone Palmitate Injection (INVEGA® SUSTENNA™)
treated group will have a statistically significant advantage on improvement in manic
symptoms. They will also have higher rate of treatment response and remission.